Literature DB >> 25949909

miR-23a blockade enhances adoptive T cell transfer therapy by preserving immune-competence in the tumor microenvironment.

Regina Lin1, John H Sampson2, Qi-Jing Li1, Bo Zhu3.   

Abstract

In adoptive T cell transfer therapy (ACT), the antitumor efficacy of cytotoxic CD8+ T lymphocytes (CTLs) has been limited by tumor-induced immunosuppression. We have demonstrated that miR-23a blockade in tumor-specific CTLs conferred resilience to TGFβ-mediated immunosuppression, resulting in superior tumor control. Our studies highlight miR-23a in tumor-specific CTLs as a clinically relevant target to enhance ACT.

Entities:  

Keywords:  TGFβ; cancer immunotherapy; cytotoxic CD8+ T lymphocytes; immune evasion; microRNA

Year:  2015        PMID： 25949909      PMCID： PMC4404905          DOI： 10.4161/2162402X.2014.990803

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

Review 1.  Progress in human tumour immunology and immunotherapy.

Authors:  S A Rosenberg
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

2.  MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells.

Authors:  Margaret S Ebert; Joel R Neilson; Phillip A Sharp
Journal:  Nat Methods       Date:  2007-08-12       Impact factor: 28.547

3.  Blimp-1 transcription factor is required for the differentiation of effector CD8(+) T cells and memory responses.

Authors:  Axel Kallies; Annie Xin; Gabrielle T Belz; Stephen L Nutt
Journal:  Immunity       Date:  2009-08-06       Impact factor: 31.745

Review 4.  Treating cancer with genetically engineered T cells.

Authors:  Tristen S Park; Steven A Rosenberg; Richard A Morgan
Journal:  Trends Biotechnol       Date:  2011-06-12       Impact factor: 19.536

5.  Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression.

Authors:  Regina Lin; Ling Chen; Gang Chen; Chunyan Hu; Shan Jiang; Jose Sevilla; Ying Wan; John H Sampson; Bo Zhu; Qi-Jing Li
Journal:  J Clin Invest       Date:  2014-10-27       Impact factor: 14.808

6.  TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance.

Authors:  Dori A Thomas; Joan Massagué
Journal:  Cancer Cell       Date:  2005-11       Impact factor: 31.743

7.  Silencing of microRNA families by seed-targeting tiny LNAs.

Authors:  Susanna Obad; Camila O dos Santos; Andreas Petri; Markus Heidenblad; Oliver Broom; Cristian Ruse; Cexiong Fu; Morten Lindow; Jan Stenvang; Ellen Marie Straarup; Henrik Frydenlund Hansen; Troels Koch; Darryl Pappin; Gregory J Hannon; Sakari Kauppinen
Journal:  Nat Genet       Date:  2011-03-20       Impact factor: 38.330

8.  Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells.

Authors:  R Derynck; J A Jarrett; E Y Chen; D H Eaton; J R Bell; R K Assoian; A B Roberts; M B Sporn; D V Goeddel
Journal:  Nature       Date:  1985 Aug 22-28       Impact factor: 49.962

9.  Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors.

Authors:  Edmund K Moon; Liang-Chuan Wang; Douglas V Dolfi; Caleph B Wilson; Raghuveer Ranganathan; Jing Sun; Veena Kapoor; John Scholler; Ellen Puré; Michael C Milone; Carl H June; James L Riley; E John Wherry; Steven M Albelda
Journal:  Clin Cancer Res       Date:  2014-06-11       Impact factor: 12.531

10.  Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model.

Authors:  Janaiah Kota; Raghu R Chivukula; Kathryn A O'Donnell; Erik A Wentzel; Chrystal L Montgomery; Hun-Way Hwang; Tsung-Cheng Chang; Perumal Vivekanandan; Michael Torbenson; K Reed Clark; Jerry R Mendell; Joshua T Mendell
Journal:  Cell       Date:  2009-06-12       Impact factor: 41.582
  10 in total
  6 in total

1.  The tumor microenvironment disarms CD8+ T lymphocyte function via a miR-26a-EZH2 axis.

Authors:  Haixia Long; Tong Xiang; Jing Luo; Fei Li; Regina Lin; Siqi Liu; Shan Jiang; Chunyan Hu; Gang Chen; Elizabeth Wong; Ying Wan; Qi-Jing Li; Bo Zhu
Journal:  Oncoimmunology       Date:  2016-10-18       Impact factor: 8.110

Review 2.  Single vs. combination immunotherapeutic strategies for glioma.

Authors:  Mayuri Chandran; Marianela Candolfi; Diana Shah; Yohei Mineharu; Viveka Nand Yadav; Carl Koschmann; Antonela S Asad; Pedro R Lowenstein; Maria G Castro
Journal:  Expert Opin Biol Ther       Date:  2017-03-20       Impact factor: 4.388

3.  MicroRNA-491 regulates the proliferation and apoptosis of CD8(+) T cells.

Authors:  Ting Yu; Qian-Fei Zuo; Li Gong; Li-Na Wang; Quan-Ming Zou; Bin Xiao
Journal:  Sci Rep       Date:  2016-08-03       Impact factor: 4.379

Review 4.  Noncoding RNAs in cancer immunity: functions, regulatory mechanisms, and clinical application.

Authors:  Le Zhang; Xiaonan Xu; Xiulan Su
Journal:  Mol Cancer       Date:  2020-03-02       Impact factor: 27.401

5.  Methylation Status of SP1 Sites within miR-23a-27a-24-2 Promoter Region Influences Laryngeal Cancer Cell Proliferation and Apoptosis.

Authors:  Ye Wang; Zhao-Xiong Zhang; Sheng Chen; Guang-Bin Qiu; Zhen-Ming Xu; Wei-Neng Fu
Journal:  Biomed Res Int       Date:  2016-03-23       Impact factor: 3.411

Review 6.  The Role of Noncoding RNAs in B-Cell Lymphoma.

Authors:  Jingwen Li; Jing Zou; Xiaoyue Wan; Chunyan Sun; Fei Peng; Zhangbo Chu; Yu Hu
Journal:  Front Oncol       Date:  2020-10-23       Impact factor: 6.244
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.